First U.S. clinical trial of autologous stem cell therapy to replace dying cells in retina.

Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD), a leading cause of vision loss among people age 65 and older. The geographic atrophy form of AMD currently has no treatment.

For more information on this clinical trial, please click the link below:

NIH launches first U.S. clinical trial of patient-derived stem cell therapy to replace dying cells in retina | National Institutes of Health (NIH)